Auven Therapeutics Announces Closing of Sale of Ocular Technologies Sarl, Holding Entity for Seciera™ for Treatment of Dry Eye Disease
January 06, 2017 08:18 ET
|
Auven Therapeutics
ST. THOMAS, U.S. Virgin Islands; LAUSANNE, Switzerland; FT. LAUDERDALE, Fla.; and HAMILTON, Bermuda, Jan. 06, 2017 (GLOBE NEWSWIRE) -- Auven Therapeutics, an international private equity company...
Auven Therapeutics Announces Sale of Ocular Technologies to Sun Pharma
October 26, 2016 11:38 ET
|
Auven Therapeutics
Ocular Technologies’ key development program asset, SecieraTM for the treatment of dry eye disease, is close to completing confirmatory Phase 3 clinical trial Auven to receive $40 million upfront...
Auven Therapeutics Announces Completion of Enrollment in Confirmatory Phase 3 Clinical Trial of Seciera (OTX‑101) for the Treatment of Dry Eye Disease
August 22, 2016 07:30 ET
|
Auven Therapeutics
Pivotal study to confirm significant improvements in tear production and ocular surface inflammation in patients with dry eye disease, with top-line results anticipated by year-end Seciera poised for...
Auven Therapeutics Announces Initiation of Confirmatory Phase 3 Clinical Trial of Seciera (OTX‑101) for the Treatment of Dry Eye Disease
March 03, 2016 08:16 ET
|
Auven Therapeutics
Study to confirm significant improvements in tear production as sole primary endpoint to support regulatory filing Commercial assessment confirms Seciera has the potential for $1 billion in...
Auven Therapeutics and Bellus Health Announce Completion of Pivotal Phase 3 Confirmatory Trial of KIACTA™ for the Treatment of Orphan Disease AA Amyloidosis
January 21, 2016 08:00 ET
|
Auven Therapeutics
ST. THOMAS, U.S. Virgin Islands, LAUSANNE, Switzerland, HAMILTON, Bermuda and LAVAL, Quebec, Jan. 21, 2016 (GLOBE NEWSWIRE) -- Auven Therapeutics, a global private equity company focused on...
Auven Therapeutics Announces Positive Results From Pivotal Clinical Trial of Seciera (OTX-101) in Dry Eye Disease
November 13, 2015 07:30 ET
|
Auven Therapeutics
Seciera demonstrated significant improvements in tear production and ocular surface inflammation
Additional pivotal Phase 3 study planned for early 2016
ST. THOMAS, U.S. Virgin Islands,...